查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014307

細胞療法市場：按類型、治療方法、給藥途徑、應用和最終用戶分類－2026-2032年全球市場預測

Cell Therapy Market by Type, Therapy Type, Mode of Administration, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，細胞治療市場價值將達到 105.4 億美元，到 2026 年將成長到 115.8 億美元，到 2032 年將達到 225 億美元，複合年成長率為 11.42%。

主要市場統計數據
基準年 2025 105.4億美元
預計年份：2026年 115.8億美元
預測年份 2032 225億美元
複合年成長率 (%) 11.42%

細胞療法正迅速崛起為現代生物醫學領域最具活力的前沿領域之一，它整合了先進的細胞工程、免疫學和再生醫學方法，以滿足尚未滿足的醫療需求。近年來，科學進展已從概念驗證（PoC）階段邁向日益成熟的臨床項目，涵蓋自體和異體構建、多種給藥方法以及不斷擴展的治療應用。隨著技術基礎的日益成熟，相關人員如今面臨著科學、監管、生產和商業性等諸多因素之間錯綜複雜的相互作用，這些因素將決定轉化研究的成敗。

本導言透過聚焦影響專案進度和商業化準備的策略轉折點，將讀者置於複雜的背景中。它還重點闡述了推動開發人員、服務供應商和臨床機構決策的趨同趨勢，例如平台標準化、模組化製造和支付方合作。重要的是，本文超越了實驗室層面，探討了實際部署中所面臨的挑戰，包括供應鏈韌性、載體生產和病患取得途徑。透過從營運角度分析現狀，本節旨在幫助領導者評估投資重點、降低風險以及哪些夥伴關係能夠加速從臨床潛力到永續治療交付的轉換。

變革性的變化正在重塑細胞療法的格局，而這種變化是由技術突破、不斷變化的監管環境、製造技術的進步以及支付方參與度的動態所驅動的。

近年來，細胞治療領域正經歷變革性的轉變，這既得益於技術突破，也得益於治療方法研發流程的系統性變革。基因編輯和模組化生產方法消除了技術瓶頸，實現了治療方案的迭代最佳化。同時，監管機構也更積極地採用適應性證據框架，這改變了研發進度，並為有條件的市場准入開闢了新的途徑。這些變化共同加速了學習週期，並促進了從早期臨床試驗到更廣泛臨床計畫的過渡。

2025 年美國關稅變化對細胞療法供應鏈的累積影響：跨境採購、組件定價和策略採購的考量。

美國2025年實施的關稅調整正在對細胞療法供應鏈、採購決策和跨國籌資策略產生連鎖反應。細胞療法研發的許多環節都依賴來自世界各地的專用試劑、一次性用品和設備，但關稅的調整改變了供應商之間的市場相對競爭力，促使專案團隊重新評估其供應商組合。因此，籌資策略正朝著地域多元化和更嚴格地篩選替代供應商的方向轉變，以規避依賴單一供應商的風險。

關鍵細分洞察揭示了治療類型、給藥途徑、臨床應用、治療來源和最終用戶如何決定開發平臺和市場進入。

透過市場區隔分析市場發現，不同的研發路徑和臨床應用案例需要獨特的策略方法。依類型分類，市場可分為「非幹細胞」和「幹細胞」兩大類。 「非幹細胞」類主要包括CAR-T細胞、樹突細胞和自然殺手細胞療法，每種療法都有其獨特的生產基礎設施和臨床終點。 「幹細胞」類則包括胚胎幹細胞、造血幹細胞和間質幹細胞，每種幹細胞都涉及不同的倫理、監管和規模化生產的考量。根據治療方法來源，療法可分為同種異體移植和自體移植。自體移植需要針對患者來源的材料建立個人化的供應鏈和物流，而同種異體移植則專注於大量生產和細胞庫保存。

影響美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和策略考量，這些因素會影響臨床試驗地點、製造地和進入。

區域趨勢對專案設計、生產策略和市場進入計畫有顯著影響，美洲、歐洲、中東和非洲以及亞太地區呈現出不同的模式。在美洲，卓越的臨床水平和健全的投資生態系統推動先進的臨床項目和大規模生產舉措，而監管路徑則優先考慮安全性和上市後證據。在歐洲、中東和非洲，跨多個司法管轄區的監管協調以及強大的臨床網路促進了跨國臨床試驗設計和生產方面的合作夥伴關係，但各國報銷框架的顯著差異可能會影響產品上市的順序。

來自主要企業的見解，重點關注細胞治療生態系統中的競爭定位、合作模式、平台專業化和差異化策略。

在整個細胞治療生態系統中運作的主要企業展現出差異化的策略，這反映了它們各自的核心能力和長期發展目標。大型製藥企業通常尋求平台收購和策略合作，以利用其商業基礎設施拓展後期產品，並將其細胞治療能力整合到更廣泛的免疫腫瘤學和再生醫學產品組合中。同時，純粹的細胞治療研發公司則傾向於專注於科學差異化，例如新型工程化構建體或獨特的細胞表現型，優先考慮轉化驗證和臨床差異化，以確保獲得合作夥伴關係和許可協議。

為產業領導者提供切實可行的建議，以加速轉化研究、最佳化供應鏈、加強與監管機構的合作，並確保永續的商業化路徑。

產業領導者應採取一系列切實可行的措施，平衡短期營運需求與長期策略定位。首先，透過設計能夠產生與監管機構和支付方均相關的終點指標的臨床試驗，將研發重點與可操作的證據生成相結合。這種雙重關注將加快市場准入談判，並降低下游談判風險。其次，透過選擇二級供應商、制定區域籌資策略以及考慮採用混合生產結構來降低關稅風險和物流脆弱性，從而投資於供應鏈韌性。

調查方法調查方法方法與資料來源、專家訪談技巧、分析架構與檢驗過程。

本調查方法結合了結構化證據整合和初步定性研究，以提供可靠且檢驗的分析結果。此方法首先對公開的科學文獻、監管指導文件、臨床試驗註冊資訊和專利趨勢進行全面回顧，從而建構對平台技術和臨床開發路徑的基礎性理解。隨後，透過對包括開發人員、生產主管、臨床研究人員和監管專家在內的專家進行有針對性的訪談，檢驗了在二次研究中提出的關鍵主題假設，從而提供了實踐背景和前瞻性觀點。

在細胞療法領域，結論是整合，重點強調了相關人員為最大限度地發揮臨床和商業性影響而面臨的策略挑戰、持續挑戰和實際途徑。

總之，本分析旨在為細胞治療生態系統中的相關人員提出一個簡潔明了的策略挑戰。儘管科學進步不斷擴大可用治療方法的範圍，但商業性成功越來越依賴生產製造、供應鏈和支付方參與方面的卓越營運。那些能夠將科學差異化與可重複、擴充性的流程以及早期價值驗證相結合的機構，將更有能力滿足監管要求並確保永續的市場進入。自體療法中物流和生產方面的差異以及區域監管碎片化等持續存在的挑戰，需要一種結合公私合營和定向投資的協作應對策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 細胞療法市場：按類型分類

  • 非幹細胞
    • CAR-T細胞
    • 樹突狀細胞
    • NK細胞
  • 幹細胞
    • 胚胎幹細胞
    • 造血幹細胞
    • 間質幹細胞

第9章 依治療方法的細胞療法市場

  • 同種
  • 自體

第10章：依給藥途徑分類的細胞療法市場

  • 肌肉內部
  • 腫瘤內部
  • 靜脈

第11章 細胞療法市場：依應用領域分類

  • 自體免疫疾病
    • 多發性硬化症
    • 類風濕性關節炎
  • 癌症治療
    • 骨髓惡性腫瘤
    • 固態腫瘤
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 再生醫學

第12章 細胞療法市場：依最終用戶分類

  • 學術和研究機構
  • 診所
  • 私人考試機構
  • 醫院

第13章 細胞療法市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 細胞療法市集：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 細胞療法市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國細胞治療市場

第17章：中國細胞治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Castle Creek Biosciences, Inc.
  • Catalent, Inc.
  • FUJIFILM Holdings Corporation
  • Gilead Sciences, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • Lonza Group Ltd.
  • Medipost Co., Ltd.
  • Mesoblast Ltd.
  • Novartis AG
  • NuVasive, Inc.
  • Pfizer Inc.
  • Sartorius AG
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • TegoScience
  • Thermo Fisher Scientific, Inc.
  • Vericel Corporation
Product Code: MRR-433AB1DC28D4

The Cell Therapy Market was valued at USD 10.54 billion in 2025 and is projected to grow to USD 11.58 billion in 2026, with a CAGR of 11.42%, reaching USD 22.50 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.54 billion
Estimated Year [2026] USD 11.58 billion
Forecast Year [2032] USD 22.50 billion
CAGR (%) 11.42%

Cell therapy has emerged as one of the most dynamic frontiers in modern biomedicine, blending advanced cellular engineering, immunology, and regenerative approaches to address unmet clinical needs. Over recent years, scientific progress has migrated from conceptual proof-of-concept work into increasingly sophisticated clinical programs that span autologous and allogenic constructs, diverse modes of administration, and a widening set of therapeutic applications. As the technology stack matures, stakeholders now confront a complex interplay of scientific, regulatory, manufacturing, and commercial forces that shape translational success.

This introduction situates readers within that complexity by focusing on the strategic inflection points that influence program progression and commercial readiness. It emphasizes the convergent trends-platform standardization, modular manufacturing, and payer engagement-that drive decision-making across developers, service providers, and clinical institutions. Importantly, the narrative moves beyond the laboratory to consider real-world implementation challenges, including supply chain resilience, vector production, and patient access pathways. By framing the landscape in operational terms, the section prepares leaders to assess where to concentrate investment, how to mitigate risk, and which partnerships accelerate movement from clinical promise to sustainable therapeutic delivery.

Transformative shifts reshaping the cell therapy landscape driven by technological breakthroughs regulatory evolution manufacturing advances and payer engagement dynamics

Recent years have produced transformative shifts across the cell therapy landscape, driven by both technological breakthroughs and systemic changes in how therapies progress to patients. Gene editing and modular manufacturing approaches have reduced technical bottlenecks and enabled iterative refinement of therapeutic constructs. In parallel, regulatory agencies have signaled greater willingness to engage in adaptive evidence frameworks, which has altered development timelines and opened new pathways for conditional market access. These changes collectively accelerate learning cycles and enable faster translation from early clinical studies into broader clinical programs.

Concurrently, commercialization dynamics have evolved as payers and providers emphasize real-world outcomes and long-term value. This shift compels sponsors to design evidence strategies that extend beyond randomized controlled trials to include registries, pragmatic studies, and health economic models. Manufacturing has also experienced a structural pivot: decentralized and hybrid production models are gaining traction as a response to logistical complexity and regional access challenges. Altogether, these transformative shifts create new opportunities for collaboration between developers, contract manufacturers, clinical centers, and payers, and they demand adaptive strategies that balance scientific ambition with operational scalability.

Cumulative implications of United States tariff changes in 2025 on cell therapy supply chains cross-border sourcing component pricing and strategic procurement considerations

The introduction of tariff changes in the United States in 2025 has exerted a cascading influence on cell therapy supply chains, procurement decisions, and cross-border sourcing strategies. While many components of cell therapy development depend on specialized reagents, disposables, and instrumentation sourced globally, tariffs have altered relative supplier economics and prompted program teams to reassess supplier portfolios. As a result, procurement strategies have shifted toward increased geographic diversification and deeper qualification of alternative suppliers to hedge against single-source exposure.

Operational responses to tariff-induced cost pressures include renegotiating supplier contracts, extending inventory lead times for critical materials, and accelerating localization of upstream activities where feasible. Manufacturing planners have evaluated the trade-off between centralized high-volume production versus regionalized, smaller-scale facilities that reduce tariff and logistics vulnerability. In parallel, clinical trial managers have adapted site selection criteria to factor in potential customs delays and reagent availability, which affects scheduling and patient enrollment pacing. These cumulative effects underscore the need for dynamic supply-chain governance, scenario planning, and proactive regulatory engagement to maintain program continuity and preserve clinical timelines despite external trade policy shifts.

Key segmentation insights revealing how therapeutic type administration route clinical application therapy origin and end users define development pipelines and market access

Deconstructing the market through segmentation reveals how different development pathways and clinical use cases necessitate distinct strategic approaches. When examined by type, the landscape is split between Non-stem Cells and Stem Cells; the Non-stem Cells category prominently includes CAR-T cells, dendritic cells, and natural killer cell programs, each with unique manufacturing footprints and clinical endpoints, while the Stem Cells category comprises embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells, which raise distinct ethical, regulatory, and scale-up considerations. Based on therapy origin, programs cluster into allogenic and autologous modalities, where autologous approaches require personalized supply chains and patient material logistics and allogenic approaches emphasize batch manufacturing and durability of cell banks.

Administration routes further differentiate development and adoption strategies: intramuscular, intratumoral, and intravenous deliveries impose varied clinical workflows, safety monitoring, and formulation stability requirements. Application-driven segmentation highlights pathway-specific needs: autoimmune disorders-such as multiple sclerosis and rheumatoid arthritis-demand chronic treatment models and long-term safety surveillance, whereas cancer treatment programs diverge between hematologic malignancies and solid tumors with corresponding differences in tumor microenvironment challenges and response metrics. Infectious disease applications span bacterial and viral infections with acute treatment timelines and distinct regulatory endpoints. Finally, end users including academic and research institutes, clinics, commercial laboratories, and hospitals each operate within different procurement, infrastructure, and reimbursement environments, which influences adoption speed and post-approval support models. Integrating these segmentation lenses enables more precise alignment of development strategies with clinical, operational, and commercial realities.

Regional dynamics and strategic considerations across Americas Europe Middle East & Africa and Asia-Pacific that influence clinical trial hubs manufacturing sites and access

Regional dynamics exert a powerful influence on program design, manufacturing strategy, and market access planning, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, centers of clinical excellence and a robust investment ecosystem drive advanced clinical programs and large-scale manufacturing initiatives, while regulatory pathways emphasize safety and post-market evidence commitments. In Europe, Middle East & Africa, regulatory harmonization across multiple jurisdictions and strong clinical networks shape multinational trial designs and collaborative manufacturing partnerships, although country-level reimbursement frameworks can vary significantly and influence launch sequencing.

Asia-Pacific presents a diverse range of clinical competencies and manufacturing capabilities, with several countries emerging as regional hubs for both early clinical development and contract manufacturing services; favorable regulatory modernization in some markets has accelerated local trial activity. Across all regions, the interplay between clinical infrastructure, talent availability, and local manufacturing incentives informs decisions on facility placement and trial execution. Moreover, cross-border collaborations, technology transfer agreements, and regional supply routes continue to evolve as stakeholders seek to balance resilience with cost efficiency and patient access imperatives.

Key company insights spotlighting competitive positioning collaboration models platform specialization and competitive differentiation strategies within cell therapy ecosystems

Key companies operating across the cell therapy ecosystem exhibit differentiated strategies that reflect their core capabilities and long-term ambitions. Large pharmaceutical firms often pursue platform acquisition and strategic partnerships to integrate cell therapy capabilities into broader immuno-oncology and regenerative portfolios, leveraging their commercial infrastructure to scale later-stage products. Pure-play cell therapy developers tend to focus on scientific differentiation-such as novel engineering constructs or unique cell phenotypes-and they prioritize translational proof and clinical differentiation to attract partnerships or licensing deals.

Providers of manufacturing and technical services emphasize scalability, quality systems, and supply-chain reliability, positioning themselves as essential enablers for companies that lack in-house production capacity. Tool and reagent suppliers differentiate through proprietary technologies, automation solutions, and validated consumables that reduce process variability. Academic spinouts and research institutes continue to serve as innovation sources, translating basic discoveries into early clinical programs. Across all these actors, collaboration models-ranging from co-development partnerships to fee-for-service arrangements-shape how capabilities are combined. Competitive differentiation increasingly hinges on demonstrated manufacturing reproducibility, regulatory readiness, and the ability to generate robust real-world evidence post-approval.

Actionable recommendations for industry leaders to accelerate translation optimize supply chains enhance regulatory engagement and secure sustainable commercial pathways

Industry leaders should pursue a set of pragmatic, actionable moves that balance near-term operability with long-term strategic positioning. First, align R&D priorities with pragmatic evidence generation by designing trials that produce both regulatory and payer-relevant endpoints; this dual focus accelerates market access discussions and reduces downstream negotiation risk. Next, invest in supply-chain resilience by qualifying secondary suppliers, developing regional sourcing strategies, and examining hybrid manufacturing footprints that reduce tariff exposure and logistical vulnerability.

Leaders must also prioritize regulatory engagement early and continuously, leveraging scientific advice and adaptive regulatory pathways to de-risk pivotal development steps and to clarify post-approval evidence commitments. Strategic partnerships merit active pursuit: form alliances with contract manufacturers, clinical networks, and technology providers to accelerate capacity build-out while preserving capital efficiency. Additionally, embed health economics and outcomes research into development plans to demonstrate value to payers and health systems; early modeling and real-world data capture will inform pricing and reimbursement strategies. Finally, cultivate operational excellence through investment in automation, digital tracking of chain-of-identity, and workforce training programs that reduce variability and accelerate time-to-patient across both autologous and allogenic programs.

Research methodology and evidence synthesis explaining data sources expert consultation methods analytical frameworks and validation processes used to build the analysis

The research methodology combines a structured evidence synthesis with primary qualitative engagement to deliver a robust, validated analysis. The approach began with a comprehensive review of publicly available scientific literature, regulatory guidance documents, clinical trial registries, and patent landscapes to develop a foundational understanding of platform technologies and clinical trajectories. This secondary research established key thematic hypotheses that were then tested through targeted expert consultations, including interviews with developers, manufacturing executives, clinical investigators, and regulatory specialists to obtain operational context and forward-looking perspectives.

Analytical frameworks employed include supply-chain mapping to identify chokepoints, segmentation analysis to align program strategy with clinical use cases, and scenario planning to assess policy and trade impacts. Findings were cross-checked through triangulation of evidence sources and validated in workshops with subject-matter experts to ensure practical relevance and to refine recommendations. Throughout, the process emphasized transparency of assumptions, traceability of evidence, and an iterative validation loop that incorporated stakeholder feedback to improve accuracy and applicability of the insights.

Concluding synthesis highlighting strategic imperatives persistent challenges and pragmatic pathways for stakeholders to maximize clinical and commercial impact in cell therapy

The conclusion synthesizes the analysis into a concise set of strategic imperatives for stakeholders across the cell therapy ecosystem. Scientific momentum continues to expand the range of viable therapeutic constructs, yet commercial success increasingly depends on operational excellence across manufacturing, supply chain, and payer engagement. Organizations that couple scientific differentiation with reproducible, scalable processes and early value demonstration will be better positioned to navigate regulatory expectations and secure durable market access. Persistent challenges-such as logistics for autologous therapies, manufacturing variability, and regional regulatory fragmentation-require coordinated response strategies that blend public-private collaboration with targeted investments.

Looking ahead, the ecosystem will reward adaptive organizations that embrace modular production models, invest in digital infrastructure for chain-of-identity and outcomes capture, and proactively engage payers to design evidence packages that reflect real-world performance. By integrating these strategic priorities with disciplined execution, stakeholders can accelerate patient access while managing the operational complexities inherent to advanced cell-based therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Therapy Market, by Type

  • 8.1. Non-stem Cells
    • 8.1.1. CAR-T Cells
    • 8.1.2. Dendritic Cells
    • 8.1.3. NK Cells
  • 8.2. Stem Cells
    • 8.2.1. Embryonic Stem Cells
    • 8.2.2. Hematopoietic Stem Cell
    • 8.2.3. Mesenchymal Stem Cell

9. Cell Therapy Market, by Therapy Type

  • 9.1. Allogenic
  • 9.2. Autologous

10. Cell Therapy Market, by Mode of Administration

  • 10.1. Intramuscular
  • 10.2. Intratumoral
  • 10.3. Intravenous

11. Cell Therapy Market, by Application

  • 11.1. Autoimmune Disorders
    • 11.1.1. Multiple Sclerosis
    • 11.1.2. Rheumatoid Arthritis
  • 11.2. Cancer Treatment
    • 11.2.1. Hematologic Malignancies
    • 11.2.2. Solid Tumors
  • 11.3. Infectious Diseases
    • 11.3.1. Bacterial Infections
    • 11.3.2. Viral Infections
  • 11.4. Regenerative Medicine

12. Cell Therapy Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Clinics
  • 12.3. Commercial Laboratories
  • 12.4. Hospitals

13. Cell Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cell Therapy Market

17. China Cell Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anterogen Co., Ltd.
  • 18.6. Astellas Pharma Inc.
  • 18.7. Athersys, Inc.
  • 18.8. BioNTech SE
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Castle Creek Biosciences, Inc.
  • 18.11. Catalent, Inc.
  • 18.12. FUJIFILM Holdings Corporation
  • 18.13. Gilead Sciences, Inc.
  • 18.14. JCR Pharmaceuticals Co., Ltd.
  • 18.15. Kolon TissueGene, Inc.
  • 18.16. Lonza Group Ltd.
  • 18.17. Medipost Co., Ltd.
  • 18.18. Mesoblast Ltd.
  • 18.19. Novartis AG
  • 18.20. NuVasive, Inc.
  • 18.21. Pfizer Inc.
  • 18.22. Sartorius AG
  • 18.23. Stemedica Cell Technologies, Inc.
  • 18.24. Stempeutics Research Pvt. Ltd.
  • 18.25. Takeda Pharmaceutical Company Limited
  • 18.26. TegoScience
  • 18.27. Thermo Fisher Scientific, Inc.
  • 18.28. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 204. GCC CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. NATO CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)